|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| A61P 35/00 | (2018.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61K 39/39558 | (2013.01) | ||
| A61K 31/475 | (2006.01) | ||
| C07K 16/2878 | (2013.01) | ||
| A61K 31/573 | (2006.01) | ||
| A61K2039/505 | (2013.01) | ||
| A61K 31/655 | (2006.01) | ||
| A61K2039/545 | (2013.01) | ||
| A61K2039/55 | (2013.01) | ||
| A61K 31/675 | (2006.01) | ||
| A61K 31/704 | (2006.01) | ||
| C07K2317/24 | (2013.01) | ||
| A61K 45/06 | (2006.01) | ||
| C07K2317/90 | (2013.01) | ||
| C07K2317/94 | (2013.01) | ||
| A61K 47/68 | (2017.01) | ||
| A61P 35/02 | (2018.01) | ||
| A61K 45/06 | (2013.01) | ||
| A61K 31/475 | (2013.01) | ||
| A61K 31/573 | (2013.01) | ||
| A61K 31/655 | (2013.01) | ||
| A61K 31/675 | (2013.01) | ||
| A61K 31/704 | (2013.01) | ||
| A61K 47/6849 | (2017.08) | ||
| A61K 47/6867 | (2017.08) | ||
| A61K 47/68031 | (2023.08) |
| (11) | Number of the document | 3538221 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17808270.7 |
| Date of filing the European patent application | 2017-11-13 | |
| (97) | Date of publication of the European application | 2019-09-18 |
| (45) | Date of publication and mention of the grant of the patent | 2024-10-09 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2017/061294 |
| Date | 2017-11-13 |
| (87) | Number | WO 2018/089890 |
| Date | 2018-05-17 |
| (30) | Number | Date | Country code |
| 201662421527 P | 2016-11-14 | US |
| (72) |
FASANMADE, Adedigbo , US
|
| (73) |
Takeda Pharmaceutical Company Limited ,
1-1, Doshomachi 4-chome,
Chuo-ku,, Osaka-shi, Osaka,
JP
|
| (54) | PEDIATRIC HUMAN DOSING OF THE ANTI-CD30 ANTIBODY-DRUG CONJUGATE BRENTUXIMAB VEDOTIN |
| PEDIATRIC HUMAN DOSING OF THE ANTI-CD30 ANTIBODY-DRUG CONJUGATE BRENTUXIMAB VEDOTIN |